Long-term Outcomes of Avelumab Plus Axitinib in Advanced Kidney Cancer in Japan
Author Information
Author(s): Kato Taigo, Furukawa Junya, Hinata Nobuyuki, Ueda Kosuke, Hara Isao, Hongo Fumiya, Mizuno Ryuichi, Okamoto Teppei, Okuno Hiroshi, Ito Takayuki, Kajita Masahiro, Oya Mototsugu, Tomita Yoshihiko, Shinohara Nobuo, Eto Masatoshi, Uemura Hirotsugu
Primary Institution: Osaka University Graduate School of Medicine
Hypothesis
Older patients may benefit less from immunotherapy due to immune senescence.
Conclusion
The study shows that avelumab plus axitinib is effective for treating advanced renal cell carcinoma in Japan, including older patients.
Supporting Evidence
- Median progression-free survival was 17.1 months.
- 1-year overall survival rate was 90.6%.
- 53.3% of patients had an objective response rate.
- Disease control rate was 88.9%.
- Median treatment duration was 10.7 months.
Takeaway
This study looked at how well a cancer treatment works for patients in Japan, especially older ones, and found it helps many people.
Methodology
A multicenter, noninterventional, retrospective study analyzing clinical data from patients treated with avelumab plus axitinib.
Potential Biases
Site selection and outcome reporting biases may affect the generalizability of the results.
Limitations
The study is retrospective, which may affect data accuracy, and it was conducted in high-volume centers, potentially introducing bias.
Participant Demographics
Median age was 70.5 years; 73.3% were male, and 89.3% had clear cell RCC.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI, 16.3–20.6 months
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website